Description
PrymaLab · Research Use Only
Tirzepatide 10mg
Not a balanced dual agonist, and the imbalance is the interesting part
Tirzepatide peptide is usually described as a dual agonist, which is accurate and incomplete. Two things about how it engages its receptors are unusual enough to have their own literature, and both of them change what a result generated with this compound is able to show.
Specification Table
| Property | Value |
|---|---|
| Compound | Tirzepatide |
| Development code | LY3298176 |
| CAS number | 2023788-19-2 |
| Residue count | Thirty-nine |
| Backbone | Based on the GIP sequence rather than on GLP-1 |
| Modification | A C20 fatty diacid attached through a linker |
| Non-natural residues | Two aminoisobutyric acid substitutions |
| Molecular weight | Approximately 4.8 kDa. Read the exact figure from the lot certificate |
| Reported targets | The GIP receptor and the GLP-1 receptor |
| Reported engagement | Greater at the GIP receptor than at the GLP-1 receptor |
| Reported signalling bias | At the GLP-1 receptor, favours cAMP generation over beta-arrestin recruitment |
| Reported internalisation | Weaker GLP-1 receptor internalisation than native GLP-1 |
| Dosing interval in published work | Once weekly, which is what the acylation supports |
| Vial | 10mg lyophilized |
| Related SKUs | Nine other fill sizes exist. The compound is identical across all of them |
| Storage | Sealed at minus 20°C. Do not freeze reconstituted solution and do not agitate |
What Does Imbalanced Mean for Tirzepatide Peptide?
A dual agonist is usually imagined as engaging both of its targets to a similar degree. Tirzepatide peptide does not.
Willard and colleagues characterised the engagement at both receptors and reported substantially greater activity at the GIP receptor than at the GLP-1 receptor.
That asymmetry is not a defect and it is not accidental. The molecule is built on the GIP sequence rather than on GLP-1, so the GIP arm is the native one and the GLP-1 activity was engineered onto a backbone that did not originally have it.
The design consequence is that the compound is closer to a GIP analogue with added GLP-1 activity than to an even split.
The experimental consequence is more concrete.
At a concentration chosen to produce a substantial GLP-1 receptor response, the GIP receptor is engaged more strongly still, so any effect observed at that concentration has a larger GIP component than the description dual agonist implies.
Anyone comparing this compound against a selective GLP-1 receptor agonist is not comparing one receptor against two. They are comparing one receptor against a weighted mixture, and the weighting matters.
Sun and colleagues later resolved structural determinants of the dual engagement, which puts the pharmacology on a structural footing rather than an inferred one.
What Does Biased Agonism Add?
The second unusual tirzepatide peptide property is separate from the first and less widely understood.
A receptor does not have one output. A class B G protein-coupled receptor engages G proteins, which generate cAMP, and separately recruits beta-arrestin, which drives desensitisation and internalisation.
A ligand that engages one of those outputs preferentially rather than both proportionally is described as biased.
Willard and colleagues reported that at the GLP-1 receptor this compound favours cAMP generation over beta-arrestin recruitment, and that it drives weaker receptor internalisation than native GLP-1 does.
The same work reported that at the GIP receptor it behaves like native GIP rather than showing bias.
So the compound is biased at one of its two receptors and not at the other, which is an unusual combination and a genuinely awkward one to reason about.
For an experiment the point is that a cAMP readout and an internalisation readout will not agree with each other in the way they would for an unbiased ligand.
Choosing one output and reporting it as receptor activation understates the situation. Reporting both, and saying which was measured, is the version that survives comparison with other work.
It is worth naming why this matters more here than it would on most compounds.
Bias is often discussed as a theoretical property with no practical consequence at the bench.
On a molecule that is already engaging two receptors unequally, a second asymmetry sitting inside one of those two arms means the readout chosen determines what is seen.
Two laboratories running the same compound at the same concentration and measuring different outputs will report different pictures, and both will be correct.
Why Does the GIP Backbone Matter?
The two receptors tirzepatide peptide engages have related ligands. GIP and GLP-1 are both incretins released from the gut, both members of the glucagon peptide family, and structurally related without being interchangeable.
Building a dual agonist on one of them rather than assembling a chimera from both is a real design choice with visible consequences.
It explains the imbalance directly, since the GIP arm is native to the sequence and the GLP-1 arm was added.
It also explains why the bias appears at the GLP-1 receptor rather than at the GIP receptor. The engineered interaction is the one that differs from a native ligand, and the native one behaves natively.
A second consequence is worth naming because it is easy to miss.
The GIP arm is the less well understood of the two in the published literature. GLP-1 receptor pharmacology has been studied for decades and has a large body of selective tools behind it, while the GIP receptor has far fewer.
That asymmetry in the tools means the arm that contributes more to this compound is the arm that is harder to isolate experimentally, which is an unhelpful combination and a real one.
The two aminoisobutyric acid substitutions in the sequence are a separate matter and they serve the usual purpose, which is to block the dipeptidyl peptidase cleavage that clears native incretins within minutes.
What Should a Study Design Account For?
Three things follow from the two tirzepatide peptide properties above, and none of them is optional if a result is going to be attributed to anything.
The first is receptor separation. Two receptors are engaged and the engagement is unequal, so a receptor-null system or a selective antagonist has to run alongside the compound rather than instead of it.
A single-arm design establishes that something in the incretin system was engaged and cannot say which part.
The second is output selection. Because the compound is biased at one receptor, the choice of readout is a design decision rather than a convenience.
A cAMP assay and an internalisation assay ask different questions here and will return different answers, and reporting one without naming it invites a comparison that does not hold.
The third is the comparator. Comparing against native GLP-1 or against a selective GLP-1 receptor agonist tests a different question from comparing against native GIP.
The published clinical work includes a direct comparison against semaglutide, reported by Frias and colleagues, and that design is instructive precisely because it holds the format constant and varies the receptor profile.
None of this is exotic. It is the ordinary discipline for a non-selective tool, applied to a compound whose non-selectivity has two dimensions rather than one.
Why Do Ten Fill Sizes Exist?
This catalogue lists tirzepatide peptide at ten quantities, from 5 milligrams to 100.
The compound is identical in every one of them. What differs is how much of it is in the vial.
That sounds trivial and it has one real consequence, which is that a larger vial is a longer relationship with a single lot.
A 100 milligram vial reconstituted for a study that runs over months is one lot, one reconstitution date and one degradation history covering the whole dataset.
That is an advantage for internal consistency and a risk for everything else, because a problem with that lot affects every result rather than some of them.
Smaller vials distribute the risk and cost more per milligram, and they introduce lot-to-lot variation into a dataset that a single large vial would not have.
Neither is correct in general. The question is whether the study would rather have one unknown applied uniformly or several unknowns distributed, and that depends on what is being measured.
What is not a reason to choose a size is the assumption that a larger vial is chemically different. It is not, and any page suggesting otherwise is describing a purchase rather than a compound.
A related point about how the sizes should be described in a methods section.
Naming the vial size is not vanity detail.
It tells a reader how many lots a dataset spans, which is the single most useful piece of provenance information a peptide study can give and the one most routinely omitted.
How Should the Vial Be Handled?
Tirzepatide peptide behaves more like a formulated protein than like a short synthetic sequence.
Sealed lyophilized powder holds at minus 20 degrees Celsius, protected from light and moisture.
Bring the vial to ambient temperature before opening, then add diluent down the wall and let the cake dissolve without agitation.
Do not vortex and do not shake. The fatty acid chain makes the molecule surface active, and an air-liquid interface is where a surface active peptide associates.
Do not freeze a reconstituted solution. Ice formation concentrates peptide into the shrinking liquid phase, which is the wrong direction for anything that self-associates.
Aliquot on first reconstitution so the working stock is opened once rather than repeatedly.
Use low-binding consumables. Adsorption on an acylated peptide at assay concentrations is large enough to move a reported potency figure.
Choose the diluent deliberately. A preserved diluent introduces a small hydrophobic molecule into a solution that already contains a hydrophobic chain, which is a decision rather than a default.
Record lot, net peptide content, diluent, storage temperature, the reconstitution date and the vial size the work came from.
Vial size belongs in the record on this compound specifically, because ten sizes exist and a reader comparing two datasets needs to know whether they came from one lot or several.
Published Literature
Selected references on the receptor pharmacology, on the structural basis of dual engagement, on the published clinical comparison and on peptide storage generally.
- Willard FS, Douros JD, Gabe MB, Showalter AD, Wainscott DB, Suter TM, et al. JCI Insight. 2020;5(17):e140532. DOI: 10.1172/jci.insight.140532
- Sun B, Willard FS, Feng D, Alsina-Fernandez J, Chen Q, Vieth M, et al. Proceedings of the National Academy of Sciences. 2022;119(13):e2116506119. DOI: 10.1073/pnas.2116506119
- Frias JP, Davies MJ, Rosenstock J, Perez Manghi FC, Fernandez Lando L, Bergman BK, et al. New England Journal of Medicine. 2021;385(6):503-515. DOI: 10.1056/NEJMoa2107519
- Manning MC, Chou DK, Murphy BM, Payne RW, Katayama DS. Pharmaceutical Research. 2010;27(4):544-575. DOI: 10.1007/s11095-009-0045-6
Frequently Asked Questions
What is tirzepatide?
Tirzepatide peptide is a thirty-nine residue synthetic sequence built on the GIP backbone and carrying a C20 fatty diacid, known in the literature as LY3298176 and carrying CAS 2023788-19-2.
Which receptors does it engage?
The GIP receptor and the GLP-1 receptor. Published characterisation reports substantially greater engagement at the GIP receptor than at the GLP-1 receptor.
What does imbalanced mean here?
That the two arms are not equal. The molecule is built on GIP, so that arm is native and the GLP-1 activity was engineered onto a backbone that did not originally have it.
Why does the imbalance matter experimentally?
Because at a concentration producing a substantial GLP-1 receptor response, the GIP receptor is engaged more strongly still. Any effect has a larger GIP component than the phrase dual agonist suggests.
What is biased agonism?
Preferential engagement of one receptor output over another. A class B receptor generates cAMP through G proteins and separately recruits beta-arrestin, and a biased ligand favours one.
Where does this compound show bias?
At the GLP-1 receptor, favouring cAMP generation over beta-arrestin recruitment and driving weaker receptor internalisation than native GLP-1. At the GIP receptor it behaves like native GIP.
How does that affect a readout?
A cAMP assay and an internalisation assay will not agree the way they would for an unbiased ligand. Naming which output was measured is part of reporting the result.
What do the aminoisobutyric acid substitutions do?
They block dipeptidyl peptidase cleavage, which clears native incretins within minutes. That is a separate matter from the receptor properties.
What should a design include?
A receptor-null system or selective antagonist alongside the compound, a stated choice of output, and a comparator chosen to test the intended question rather than the convenient one.
Is the compound different in different vial sizes?
No. It is identical across all ten sizes in this catalogue. What differs is how much is in the vial and therefore how long one lot covers a study.
Is a larger vial better?
Neither is correct in general. A large vial gives one lot and one degradation history across a dataset, which helps consistency and concentrates risk. Smaller vials distribute both.
What belongs in the record?
Lot, net peptide content, diluent, storage temperature, reconstitution date and the vial size. Vial size matters here because ten exist and a reader needs to know whether two datasets share a lot.
Compliance Statement
Tirzepatide is sold exclusively for laboratory research use. It is not a drug, food, or cosmetic product, and it is not a dietary product of any kind. It is not approved by the FDA or any comparable authority for human or veterinary use, it engages two receptors unequally and published findings cannot be attributed to either of them without a receptor-null system or a selective antagonist run alongside, it shows signalling bias at one of those two receptors so different assay outputs will not agree with one another, its published clinical record was generated with an approved formulation that is not the article supplied here, and no compound in this range is offered for any human or veterinary purpose. This product is not intended to diagnose, treat, cure, or prevent any disease. It must not be given to humans or animals. Purchase is restricted to qualified researchers and institutions operating within applicable laws. All handling is the responsibility of the purchasing laboratory.
Other formats of Tirzepatide
Tirzepatide is also stocked as Tirzepatide 5mg, Tirzepatide 15mg, Tirzepatide 20mg, Tirzepatide 30mg, Tirzepatide 40mg, Tirzepatide 50mg, Tirzepatide 60mg and Tirzepatide 80mg. Each listing states its own quantity and concentration, and the pen and vial comparison explains what changes between formats.
19 reviews for Tirzepatide 10mg